Riluzole利鲁唑,1744-22-5

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Riluzole

CAS No. : 1744-22-5

MCE 国际站：Riluzole

产品活性：Riluzole 是一种抗惊厥活性分子，属于依赖于使用的钠通道阻滞剂家族，它也可以抑制 GABA 摄取，其 IC₅₀ 值为 43 μM。

研究领域：Membrane Transporter/Ion Channel  |  Neuronal Signaling

作用靶点：Sodium Channel  |  GABA Receptor

In Vitro: Riluzole is an anticonvulsant drug and belongs to the family of use-dependent Na⁺ channel blocker which can also inhibit GABA uptake with an IC₅₀ of 43 μM. At 20 μM, Riluzole inhibits peak autaptic IPSCs only slightly but prolongs IPSCs reliably. It is also found that Riluzole causes a strong, concentration-dependent, readily reversible enhancement of responses to 2 μM GABA. At higher concentrations of Riluzole, especially 300 μM, GABA currents exhibit apparent desensitization during prolonged co-exposure to 2 μM GABA and Riluzole. The EC₅₀ of Riluzole potentiation of GABA responses is about 60 μM.

In Vivo: In normal na ve rats, systemic injection of Riluzole (8 mg/kg, i.p.; n=6 rats) decreases the duration of ultrasonic but not audible vocalizations evoked by noxious stimulation of the knee joint compare to vehicle tested in the same rats (P<0.05). Systemic application of Riluzole (8 mg/kg, i.p.; n=19 rats) decreases the vocalizations of arthritic rats compare to predrug and vehicle significantly (P<0.05 to 0.001). Riluzole administered into the CeA significantly decreases the duration of audible and ultrasonic vocalizations evoked by noxious stimulation of the knee compare to predrug values (n=8 rats; P<0.05 to 0.01).

相关产品：Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  Membrane Transporter/Ion Channel Compound Library  |  Neuronal Signaling Compound Library  |  FDA-Approved Drug Library  |  Anti-Cancer Compound Library  |  CNS-Penetrant Compound Library  |  Drug Repurposing Compound Library  |  NMPA-Approved Drug Library  |  Orally Active Compound Library  |  Neurotransmitter Receptor Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  Anti-Alzheimer's Disease Compound Library  |  Neuroprotective Compound Library  |  Drug-Induced Liver Injury (DILI) Compound Library  |  Anti-Parkinson's Disease Compound Library  |  Neurodegenerative Disease-related Compound Library  |  Rare Diseases Drug Library  |  EMA-Approved Drug Library  |  Sodium Channel Blocker Library  |  GABA Receptor Compound Library  |  FDA-Approved Anticancer Drug Library  |  Human Metabolite Library  |  Non-steroidal Anti-Inflammatory Compound Library  |  Heterocyclic Compound Library  |  Off-patent Drug Library  |  Membrane Protein-targeted Compound Library  |  Membrane Receptor-targeted Compound Library  |  Ion Channel Compound Library  |  Bicuculline  |  Amiloride hydrochloride  |  γ-Aminobutyric acid  |  Picrotoxin  |  Aminooxyacetic acid hemihydrochloride  |  Halofuginone  |  Propofol  |  Carbamazepine  |  Gabazine  |  Furosemide  |  20(S)-Ginsenoside Rg3  |  TPC2-A1-P  |  Baclofen  |  Lidocaine  |  Amitriptyline hydrochloride  |  Amentoflavone  |  Veratridine  |  5-(N,N-Hexamethylene)-amiloride  |  Triamterene  |  Zuranolone  |  Fluphenazine dihydrochloride  |  Lamotrigine  |  Flunarizine dihydrochloride  |  QX-314 chloride  |  CGP52432  |  Phenytoin  |  Vigabatrin  |  A-803467  |  Ranolazine  |  Flumazenil

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds